Loading market dashboard
Ostin Technology Group Co., Ltd.
OSTTechnologyNASDAQCN
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs.
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma during the 2026 American Society of Clinical Oncologists (ASCO) Annual Meeting being held from May 28, 2026 to June 2, 2026. New York, New York and Rockville, Maryland--(Newsfile Corp. - May 29, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced the publication of four articles related to OST-HER2 and/or Osteosarcoma in Drug Discovery World.
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma ("Metastatic Osteosarcoma") 2.5-year overall survival data expected to be released during ASCO 2026 EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA ("FDA") Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma OS Animal Health S-1 filing for proposed 'Go-Public' transaction and receipt of SEC comments New York, New York and Rockville, Maryland--(Newsfile Corp. - May 18, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, reported first quarter 2026 financial results and provided a business update centered on the Company's lead program for OST-HER2 in the prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma ("Metastatic Osteosarcoma").
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026 Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval Program Commercialization and reimbursement preparations well underway for the U.S., U.K., and Europe in parallel with ongoing partnership discussions New York, New York and Rockville, Maryland--(Newsfile Corp. - May 14, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, announced Dr. Craig Eagle's appointment as Chief Medical Advisor. His appointment strengthens the Company's medical, regulatory, and commercial leadership team in preparation for potential early market access decisions from regulators at the U.S. Food & Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), European Medicines Agency (EMA) and Australian Therapeutic Good Administrations (ATGA) for OST-HER2 in the prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program").
30/04/2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. CLARIANE SE Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 28/04/2026] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
30/04/2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. BEFIMMO Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 28/04/2026] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2 approach. Participants will include strategic advisors Dr. Craig Eagle and Dr. Bob Langer, and Osteosarcoma key opinion leader Dr. Peter Anderson from Cleveland Clinic.
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetings Remaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meetings with EU EMA and Australian TGA New York, New York--(Newsfile Corp. - April 27, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that it will be hosting a conference call on Thursday April 30, 2026 at 8:30am ET to review the data that supported the recent Patent Cooperation Treaty (PCT) international application for a OST-HER2 pharmacodynamic biomarker 1 (the "OST-HER2 Immune Signature") as a surrogate clinical efficacy endpoint. The OST-HER2 Immune Signature is expected to be used to support early market access in the second half of 2026 in the U.S via a Biologics License Application ("BLA") under the Accelerated Approval Program 2 (Accelerated Approval), in addition to Europe, the UK and Australia via Conditional Marketing Authorisations 3 (CMAs).
New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ostin (OST) To Contact Him Directly To Discuss Their Options
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
New York, New York--(Newsfile Corp. - April 16, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
Key Dates and Disclosure Events Shareholders Need to Know April 14, 2025: OST closes at $0.78. April 15, 2025: A $5 million registered direct offering closes, placing shares with select participants at $0.55 each.
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference call later in April 2026 to review new biomarker signature Biomarker signature meets pharmacodynamic/response criteria established by FDA's Biomarkers, EndpointS and other Tools (BEST) program for use as a surrogate clinical endpoint of 1-year event free survival and 2-year overall survival in OST-HER2's Phase 2b trial in the prevention of delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma to support a BLA submission under FDA's Accelerated Approval Program New York, New York--(Newsfile Corp. - April 16, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that it has filed a new patent application covering a unique immune signature in response to treatment with therapeutic candidates developed from the Company's proprietary Listeria monocytogenes platform ('Listeria') based on new biomarker data from the Company's Phase 2b trial of OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. Filed claims include treatment with Listeria leading to the downregulation of genes associated with tumor and circulating tumor cell immune evasion in combination with the upregulation of genes associated with cytotoxic cellular immune activation leads to improved anti-tumor cellular immunity activation.
New York, New York--(Newsfile Corp. - April 15, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, April 15, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ostin (OST) To Contact Him Directly To Discuss Their Options
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (“Ostin” or the “Company”) (NASDAQ: OST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ostin Technology Group Co., Ltd., (“Ostin” or the "Company") (NASDAQ: OST) investors off a class action on behalf of investors that bought securities between May 11, 2025 and June 26, 2025, inclusive (the “Class Period”). Ostin investors have until April 17, 2026 to file a lead plaintiff motion.
Executive Accountability: Qiaoyun Xie Named as Defendant in Securities Action Alleging She Certified Financials While Fraudulent Scheme Unfolded Executive Accountability: Qiaoyun Xie Named as Defendant in Securities Action Alleging She Certified Financials While Fraudulent Scheme Unfolded
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (“Ostin” or the “Company”) (NASDAQ: OST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors that Qiaoyun Xie, Chief Financial Officer of Ostin Technology Group Co., Ltd. (Nasdaq: OST), is named as a defendant in a securities class action filed in the United States District Court for the Southern District of New York.
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ostin Technology Group Co., Ltd.
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, April 1, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (“Ostin” or the “Company”) (NASDAQ: OST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors that Qiaoyun Xie, Chief Financial Officer of Ostin Technology Group Co., Ltd. (Nasdaq: OST), is named as a defendant in a securities class action filed in the United States District Court for the Southern District of New York.
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, March 26, 2026 /PRNewswire/ -- April 14, 2025: OST closes at $0.78. April 15, 2025: A $5 million registered direct offering closes, placing shares with select participants at $0.55 each.
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, March 25, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (“Ostin” or the “Company”) (NASDAQ: OST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK--(BUSINESS WIRE)--The absence of Wall Street analyst coverage of Ostin Technology Group Co., Ltd. (Nasdaq: OST) left retail investors without any independent professional assessment as the stock surged 1,175% on fabricated demand. Find out if you can recover your OST investment losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. OST shares collapsed from $9.40 to $0.55 on June 26, 2025, a loss of $8.85 per share (94.1%), destroying over $950.
NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Thousands of retail investors across six countries believed they had found a once-in-a-lifetime opportunity in Ostin Technology Group Co., Ltd. (Nasdaq: OST).
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ostin Technology Group Co., Ltd. (NASDAQ:OST) and NuScale Power Corporation (NYSE:SMR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, March 19, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, March 18, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (“Ostin” or the “Company”) (NASDAQ: OST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Thousands of retail investors across six countries believed they had found a once-in-a-lifetime opportunity in Ostin Technology Group Co., Ltd. (Nasdaq: OST).
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ostin Technology Group Co., Ltd., (“Ostin” or the "Company") (NASDAQ: OST) investors off a class action on behalf of investors that bought securities between May 11, 2025 and June 26, 2025, inclusive (the “Class Period”). Ostin investors have until April 217, 2026 to file a lead plaintiff motion.
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ostin Technology Group Co., Ltd. (NASDAQ: OST).
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) and certain of its officers.
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. ("Ostin" or the "Company") (NASDAQ: OST).
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, March 12, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
Promise vs. Reality: The Ostin Technology Performance Gap That Cost Investors $950 Million NEW YORK, March 11, 2026 /PRNewswire/ -- The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium.
NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ostin Technology Group Co., Ltd. ("Ostin Technology Group Co., Ltd.
